No Data
No Data
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and BridgeBio Pharma (BBIO)
Express News | BridgeBio Pharma Inc : Mizuho Raises Target Price to $60 From $53
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $60
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Express News | Form 144 | BridgeBio Pharma(BBIO.US) Director Proposes to Sell 3.52 Million in Common Stocks